Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 14/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4983756 | 0.79 | GRIA4 (0.36) | BDKRB1GRIA4ALOX5APFEN1 | |
| SCHEMBL4988410 | 0.78 | BDKRB1 (0.36) | BDKRB1 | |
| SCHEMBL4981006 | 0.78 | CTSA (0.41) | BDKRB1 | |
| SCHEMBL4988415 | 0.73 | BDKRB1 (0.34) | BDKRB1ALOX5APFEN1 | |
| SCHEMBL4987228 | 0.72 | BDKRB1 (0.71) | BDKRB1 | |
| SCHEMBL18040183 | 0.69 | PDE2A (0.43) | — | |
| SCHEMBL18040182 | 0.69 | PDE2A (0.43) | — | |
| SCHEMBL4983679 | 0.68 | APLNR (0.41) | — | |
| SCHEMBL20238681 | 0.68 | KMT2A (0.41) | — | |
| SCHEMBL20238525 | 0.68 | KMT2A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332499-B2 | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides | MERCK & CO., INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060247229-A1 | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides | MERCK SHARP & DOHME CORP. | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247229-A1 | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides | BDKRB1, BDKRB2, CNR2 | BDKRB1 1/4885GRIA4 568/4885ALOX5AP 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.